CTOs on the Move

Novome Biotechnologies

www.novomebio.com

 
Novome Biotechnologies is engineering bacteria from the human gut to treat diseases. Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Novome Biotechnologies raised $33M on 01/07/2020

Similar Companies

Hydromer

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients needs. Hydromer collaborates extensively with clients to deliver superior, customized polymer-based solutions. We create or modify coating formulations that adhere to a multitude of substrates and match the unique requirements and geometries of any device. We are a leader in developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We offer custom industrial and medical device coatings, contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. Hydromer`s technologies enhance the value of our clients products by delivering lubricity, thromboresistance, anti-fogging, antimicrobial, and other properties. Our coatings aid in the manufacture of medical devices, aerospace components, cosmetics, and products in a variety of industries. We are an FDA, GMP/ISO 13485, and ISO 9001 production facility.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.

Organix Inc.

Organix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Dalton Pharma Services

Dalton Pharma Services is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strides Inc

Strides Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.